Log In
Print
BCIQ
Print
Print this Print this
 

IRT-101, IRT101

  Manage Alerts
Collapse Summary General Information
Company Immune Therapeutics Inc.
DescriptionLymphocytes incubated methionine enkephalin that are re-infused into a patient
Molecular Target Opioid receptor (OPR)
Mechanism of ActionOpioid receptor antagonist
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner

Hubei Qianjiang Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today